Crohn's Disease Treatment Studies

If you are looking for clinical trials for Crohn's disease you have come to the right place! As researchers, our goal is to discover new therapies and information about Inflammatory Bowel Disease (IBD), but most importantly, provide an alternate therapy that helps YOU. We welcome you to the IBD Research Team and encourage you to look at the studies below that you may qualify for. We will update this site periodically, so keep checking this page for new studies. If you have ANY questions or are interested in participating please feel free to call (734) 615-4843 or e-mail higginsSCteam@umich.edu. We hope to hear from you soon!


Bergamot

A phase III, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of etrolizumab as an induction and maintenance treatment for patients with moderately to severely active Crohn's disease

Enrollment status: OPEN

Study Coordinator: Kay Sauder

Drug: etrolizumab (anti-integrin β7), injection under the skin

This is a phase 3 study for patients with moderate to severely active Crohn's disease to evaluate the safety and effectiveness of etrolizumab, a β7 anti-integrin that acts on the lining of the gut to block white blood cell trafficking. The study lasts up to 72 weeks and involves a screening visit, baseline enrollment visit, and follow-up drug administration visits every 4 weeks. Patients are also required to have a colonoscopy done at screening, week 14, and week 72 to assess disease activity and response to study medication. Patients who enroll in the study will be randomly assigned to etrolizumab or placebo (inactive medication). All patients have a 20% chance of receiving placebo. After completing the Bergamot study, patients have the option to roll over into the open-label portion of the study known as Juniper, and receive active study medication for up to 6 years or until the medication is approved by the FDA.


Pioneer

A randomized, double-blind, placebo-controlled trial to evaluate the effectiveness of a nutritional intervention in improving the intestinal mucosal health status in subjects with Crohn’s disease (CD) receiving induction anti-TNF therapy

Enrollment status: OPEN

Study Coordinator: Angela Theil

Nutritional study

This study is to evaluate the effectiveness of an orally administered medical food in moderately to severely active subjects receiving induction therapy for Remicade® or Humira®.


DINE

Open label, randomized, multicenter, comparative effectiveness trial of specific carbohydrate and Mediterranean diets to induce remission in patients with Crohn's Disease

Enrollment status: OPEN

Study Coordinator: TBA

Dietary study

This protocol is designed to compare the effectiveness of two dietary interventions for patients with Crohn's disease (CD): the specific carbohydrate diet (SCD) and a Mediterranean style diet (MSD) that has been demonstrated to have numerous other health benefits. The two diets will be compared in terms of their ability to resolve both the symptoms and bowel inflammation that characterize this debilitating disease.


APD371 Cannabinoid

A phase 2a study to determine the tolerability and effectiveness of APD371 in patients with mildly active Crohn's Disease with abdominal pain

Enrollment status: OPEN

Study Coordinator: TBA

Drug: APD371, oral tablet